---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-009673"
form_type: "8-K"
ticker: "ABBV"
cik: "0001551152"
company_name: "AbbVie Inc."
filed_at: "2025-02-05T23:59:59+00:00"
generated_at: "2026-05-27T02:38:15.079480+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# AbbVie enters $3.0 billion revolving credit facility maturing in 2030

## Summary
- On January 30, 2025, AbbVie entered a $3.0 billion unsecured revolving credit agreement with JPMorgan Chase as agent.
- The new facility matures on January 30, 2030, and AbbVie had no borrowings outstanding on the effective date.
- AbbVie's existing $5.0 billion revolver maturing in March 2028 remains in effect, bringing total revolving capacity to $8.0 billion.
- Borrowings under the facility bear variable interest rates and are subject to customary covenants.

## SEC filing metadata
- accession: 0001104659-25-009673
- form_type: 8-K
- ticker: ABBV
- cik: 0001551152
- company_name: AbbVie Inc.
- filed_at: 2025-02-05T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1551152/000110465925009673/0001104659-25-009673-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1551152/000110465925009673/tm255474d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-009673
- JSON: https://secwatch.observer/filing/0001104659-25-009673.json
- Plain text: https://secwatch.observer/filing/0001104659-25-009673.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.